MINNEAPOLIS & SAN ANTONIO--(BUSINESS WIRE)--Nov. 17, 2009-- Medtronic, Inc. (NYSE:MDT) today announced the grand opening of its new Diabetes Therapy Management and Education Center in San Antonio. The new operation provides customer care and education for patients and healthcare professionals using Medtronic insulin pumps, continuous glucose monitoring and therapy management software for the treatment of diabetes.
Company officials and San Antonio community representatives cut the ribbon at the Center, which currently employs more than 200 diabetes therapy professionals dedicated to supporting Medtronic customers. The company anticipates hiring nearly 1,400 people within the next five years.
“Not only is this facility a Center of Excellence for diabetes therapy management, it supports Medtronic’s commitment to accelerating the pace of innovation to improve patients’ lives,” said Katie Szyman, president of the Diabetes business and senior vice president at Medtronic. “We are delighted to be able to expand our business operations in the San Antonio community, as well as support South Texas by bringing new jobs to the area.”
Medtronic’s Diabetes Therapy Management and Education Center is fully integrated with the Diabetes business, which is based in Northridge, Calif., and focused on providing customer experience excellence. Medtronic continues to invest in both its Northridge and San Antonio operations to provide world class customer care.
About the Diabetes Business at Medtronic
The Diabetes business at Medtronic (www.medtronicdiabetes.com) is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.
Source: Medtronic, Inc.
Medtronic, Inc.
Public Relations
Steve Cragle, 763-505-2345
or
Investor Relations
Jeff Warren, 763-505-2696
